|Other names||MIN-101; CYR-101; MT-210|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||366.436 g/mol g·mol−1|
|3D model (JSmol)|
Roluperidone (former developmental code names MIN-101, CYR-101, MT-210) is a 5-HT2A and σ2 receptor antagonist that is under development by Minerva Neurosciences for the treatment of schizophrenia. One of its metabolites also has some affinity for the H1 receptor. As of May 2018, the drug is in phase III clinical trials.
See also: Receptor/signaling modulators
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|